Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4

Celldex Therapeutics, Inc.

2025-FY EPS reported -$3.90 revenue$1,545,000

Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.
Phase 2 prurigo nodularis and atopic dermatitis studies fully enrolled; data expected summer and late 2026.
Phase 1 CDX-622 (bispecific SCF & TSLP) proof-of-mechanism study in mild-to-moderate asthma initiated.
Q4 2025 net loss $81.3M ($1.22 per share) vs $47.1M ($0.71) year ago; R&D spend rose to $75.3M.
Cash, cash equivalents and marketable securities $518.6M at Dec 31, 2025; runway through 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.